News: General News

Study suggests that annual CA125 screening may reduce ovarian cancer deaths

Initial results from the world’s largest ovarian cancer screening trial suggest that tracking levels of a cancer-associated protein over time may help reduce ovarian cancer deaths by as much as 20 percent. Results of the 14-year study, led by investigators at University College London (UCL), are being published online in The Lancet.

The U.K. Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) enrolled more than 200,000 women across the U.K. to investigate whether annual screening with a blood test utilizing the Risk of Ovarian Cancer Algorithm (ROCA), co-developed by Steven Skates, PhD, of the Massachusetts General Hospital (MGH) Biostatistics Unit, can reduce ovarian cancer deaths. ROCA analyzes the results of annual blood tests for CA125, a protein known to be elevated in the blood of women with ovarian cancer.

Get the full story here